CL2014002631A1 - Anticuerpos anti - hla - b*27 y usos de estos - Google Patents

Anticuerpos anti - hla - b*27 y usos de estos

Info

Publication number: CL2014002631A1
Authority: CL; Chile
Prior art keywords: hla antibodies; hla; antibodies
Prior art date: 2012-04-02

Application number

CL2014002631A

Other languages

English (en)

Inventor

Andrew J Murphy

Ana Kostic

Original Assignee

Regeneron Pharma

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-04-02

Filing date

2014-09-30

Publication date

2015-01-16

2014-09-30 Application filed by Regeneron Pharma filed Critical Regeneron Pharma

2015-01-16 Publication of CL2014002631A1 publication Critical patent/CL2014002631A1/es

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2833—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Physical Education & Sports Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Rheumatology (AREA)
Transplantation (AREA)
Ophthalmology & Optometry (AREA)
Neurology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

CL2014002631A 2012-04-02 2014-09-30 Anticuerpos anti - hla - b*27 y usos de estos CL2014002631A1 (es)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201261618969P	2012-04-02	2012-04-02
US201361778703P	2013-03-13	2013-03-13

Publications (1)

Publication Number	Publication Date
CL2014002631A1 true CL2014002631A1 (es)	2015-01-16

Family

ID=48093122

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CL2014002631A CL2014002631A1 (es)	2012-04-02	2014-09-30	Anticuerpos anti - hla - b*27 y usos de estos

Country Status (22)

Country	Link
US (1)	US9790273B2 (es)
EP (1)	EP2834272B1 (es)
JP (1)	JP6320993B2 (es)
KR (1)	KR20150003256A (es)
CN (1)	CN104169302A (es)
AR (1)	AR090585A1 (es)
AU (1)	AU2013243644C1 (es)
BR (1)	BR112014024622A2 (es)
CA (1)	CA2868907C (es)
CL (1)	CL2014002631A1 (es)
CO (1)	CO7121320A2 (es)
EA (1)	EA201491827A1 (es)
HK (1)	HK1207092A1 (es)
IL (2)	IL234707A0 (es)
MX (1)	MX365690B (es)
MY (1)	MY171180A (es)
NZ (1)	NZ700650A (es)
PH (1)	PH12014502184A1 (es)
SG (2)	SG11201405759UA (es)
TW (1)	TWI619729B (es)
UY (1)	UY34721A (es)
WO (1)	WO2013152001A2 (es)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IN2014DN10515A (es)	2006-03-31	2015-08-21	Chugai Pharmaceutical Co Ltd
MX336725B (es)	2007-09-26	2016-01-28	Chugai Pharmaceutical Co Ltd	Metodo de modificacion del punto isoelectrico de anticuerpos medinate la sustitucion de aminoacidos en region de determinacion de complementariedad (cdr).
TWI700293B (zh)	2008-04-11	2020-08-01	日商中外製藥股份有限公司	重複結合複數個抗原的抗體
KR102568454B1 (ko)	2010-11-30	2023-08-18	추가이 세이야쿠 가부시키가이샤	복수 분자의 항원에 반복해서 결합하는 항원 결합 분자
EP3604330A1 (en)	2011-02-25	2020-02-05	Chugai Seiyaku Kabushiki Kaisha	Fcgammariib-specific fc antibody
US9890218B2 (en)	2011-06-30	2018-02-13	Chugai Seiyaku Kabushiki Kaisha	Heterodimerized polypeptide
JP6322411B2 (ja)	2011-09-30	2018-05-09	中外製薬株式会社	複数の生理活性を有する抗原の消失を促進する抗原結合分子
BR112014013081A2 (pt)	2011-11-30	2020-10-20	Chugai Seiyaku Kabushiki Kaisha	veículo contendo fármaco em célula para formação de um complexo imune
TWI619729B (zh)	2012-04-02	2018-04-01	再生元醫藥公司	抗－ｈｌａ－ｂ*２７抗體及其用途
ES2719720T3 (es)	2012-07-27	2019-07-12	Hope City	Una vacuna de MVA para la administración de un complejo de UL128 y para prevenir la infección por CMV
TWI855488B (zh)	2012-08-24	2024-09-11	日商中外製藥股份有限公司	FcγRIIb特異性Fc區域變異體
EP3597747B1 (en)	2012-08-24	2023-03-15	Chugai Seiyaku Kabushiki Kaisha	Mouse fcgammarii-specific fc antibody
ES2876009T3 (es)	2012-12-27	2021-11-11	Chugai Pharmaceutical Co Ltd	Polipéptido heterodimerizado
AU2014250434B2 (en)	2013-04-02	2019-08-08	Chugai Seiyaku Kabushiki Kaisha	Fc region variant
KR101838645B1 (ko) *	2014-12-19	2018-03-14	추가이 세이야쿠 가부시키가이샤	항-c5 항체 및 그의 사용 방법
TWI656133B (zh)	2014-12-19	2019-04-11	日商中外製藥股份有限公司	抗肌抑素之抗體、含變異Ｆｃ區域之多胜肽及使用方法
JP6792559B2 (ja) *	2015-02-04	2020-11-25	ウニヴェルズィテートチューリッヒ	癌治療のためのｈｌａホモ二量体の使用
WO2016125495A1 (en)	2015-02-05	2016-08-11	Chugai Seiyaku Kabushiki Kaisha	Antibodies comprising an ion concentration dependent antigen-binding domain, fc region variants, il-8-binding antibodies, and uses therof
KR102632082B1 (ko)	2015-02-27	2024-02-02	아이셀 진 테라퓨틱스 엘엘씨	혈액 악성종양을 표적으로 하는 키메라 항원 수용체(car), 조성물 및 이의 용도
US11173179B2 (en)	2015-06-25	2021-11-16	Icell Gene Therapeutics Llc	Chimeric antigen receptor (CAR) targeting multiple antigens, compositions and methods of use thereof
JP6961497B2 (ja)	2015-06-25	2021-11-05	アイセル・ジーン・セラピューティクス・エルエルシー	キメラ抗体受容体（ＣＡＲｓ）の構成およびその使用方法
CA2996299C (en)	2015-08-24	2022-09-27	University Of Cincinnati	Methods and compositions for the detection of fc receptor binding activity of antibodies
EP3347045A4 (en)	2015-09-10	2019-08-28	City of Hope	MVA-GH / GL-PC VACCINATED ANTIBODIES FOR NEUTRALIZING THE INFECTIOSITY OF HUMAN CYTOMEGALOVIRUS AND METHOD THEREFOR
AR107078A1 (es) *	2015-12-18	2018-03-21	Chugai Pharmaceutical Co Ltd	Anticuerpo antimiostatina, polipéptidos que contienen regiones fc variantes así como métodos de uso
KR102467124B1 (ko) *	2015-12-18	2022-11-15	추가이 세이야쿠 가부시키가이샤	항-c5 항체 및 사용 방법
WO2017110981A1 (en)	2015-12-25	2017-06-29	Chugai Seiyaku Kabushiki Kaisha	Anti-myostatin antibodies and methods of use
JP6980196B2 (ja)	2016-03-08	2021-12-15	ウニヴェルズィテートチューリッヒ	Ｈｌａ−ｂ５７オープンコンフォーマー
JP7114490B2 (ja)	2016-06-24	2022-08-08	アイセル・ジーン・セラピューティクス・エルエルシー	キメラ抗体受容体（ＣＡＲｓ）の構成およびその使用方法
CN109689099B (zh)	2016-08-05	2023-02-28	中外制药株式会社	用于预防或治疗il-8相关疾病的组合物
US11279747B2 (en)	2016-08-10	2022-03-22	Universitat Zurich	MHC class Ia fusion dimers for treatment of cancer
WO2018139623A1 (en)	2017-01-30	2018-08-02	Chugai Seiyaku Kabushiki Kaisha	Anti-sclerostin antibodies and methods of use
CN110520145A (zh) *	2017-03-31	2019-11-29	阿尔玛生物医疗公司	Hla-b27相关炎性疾病的治疗方法及相关组合物
EP3641768B1 (en)	2017-06-21	2025-12-31	iCell Gene Therapeutics LLC	Chimeric Antigen Receptors (CARs), Compositions and Associated Methods
EP3710589A4 (en)	2017-11-14	2021-11-10	Chugai Seiyaku Kabushiki Kaisha	ANTI-C1S ANTIBODIES AND METHOD OF USING
CN108486226B (zh) *	2018-04-01	2022-04-12	广东辉锦创兴生物医学科技有限公司	Hla-b27等位基因的检测试剂盒及其应用
KR102697702B1 (ko)	2018-08-10	2024-08-22	추가이 세이야쿠 가부시키가이샤	항cd137 항원 결합 분자 및 그의 사용
WO2020188573A1 (en) *	2019-03-21	2020-09-24	Gamida-Cell Ltd.	Expanded nk cell fractions for transplantation in combination therapy
BR112021021689A2 (pt)	2019-05-15	2022-03-22	Chugai Pharmaceutical Co Ltd	Molécula de ligação a antígeno, composição farmacêutica, e método
CN111175490A (zh) *	2020-01-19	2020-05-19	泛肽生物科技(浙江)有限公司	一种定性检测hla-b27的试剂盒及其检测方法
CA3215902A1 (en)	2021-04-07	2022-10-13	Regeneron Pharmaceuticals, Inc.	A composition for use in treating mhc-1-opathies
WO2023064850A1 (en) *	2021-10-14	2023-04-20	Regeneron Pharmaceuticals, Inc.	Treatment of uveitis with endoplasmic reticulum aminopeptidase 1 (erap1) inhibitors
US20250302956A1 (en) *	2022-05-13	2025-10-02	Memorial Sloan-Kettering Cancer Center	Compositions and methods for modulating tcr specificity

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0213824B1 (en) *	1985-08-16	1995-05-24	Genetic Systems Corporation	Monoclonal antibody to polymorphic HLA determinant-B27
US5369010A (en)	1985-08-16	1994-11-29	Genetic Systems Corporation	Monoclonal antibody to polymorphic HLA determinant -B27
IL85035A0 (en)	1987-01-08	1988-06-30	Int Genetic Eng	Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
EP0940468A1 (en)	1991-06-14	1999-09-08	Genentech, Inc.	Humanized antibody variable domain
US5734023A (en) *	1991-11-19	1998-03-31	Anergen Inc.	MHC class II β chain/peptide complexes useful in ameliorating deleterious immune responses
US6596541B2 (en)	2000-10-31	2003-07-22	Regeneron Pharmaceuticals, Inc.	Methods of modifying eukaryotic cells
US7850962B2 (en)	2004-04-20	2010-12-14	Genmab A/S	Human monoclonal antibodies against CD20
RS52176B (sr)	2006-06-02	2012-08-31	Regeneron Pharmaceuticals Inc.	Antitela visokog afiniteta prema humanom il-6 receptoru
US20130315933A1 (en)	2010-10-06	2013-11-28	Christoph Renner	Antibodies Directed Against HLA-B27 Homodimers and Methods and Uses Thereof in Diagnosis and Therapy
TWI619729B (zh)	2012-04-02	2018-04-01	再生元醫藥公司	抗－ｈｌａ－ｂ*２７抗體及其用途

2013
- 2013-04-01 TW TW102111629A patent/TWI619729B/zh not_active IP Right Cessation
- 2013-04-02 EA EA201491827A patent/EA201491827A1/ru unknown
- 2013-04-02 AU AU2013243644A patent/AU2013243644C1/en not_active Ceased
- 2013-04-02 HK HK15107698.3A patent/HK1207092A1/xx unknown
- 2013-04-02 MX MX2014011898A patent/MX365690B/es active IP Right Grant
- 2013-04-02 CA CA2868907A patent/CA2868907C/en active Active
- 2013-04-02 WO PCT/US2013/034952 patent/WO2013152001A2/en not_active Ceased
- 2013-04-02 US US13/855,448 patent/US9790273B2/en not_active Expired - Fee Related
- 2013-04-02 MY MYPI2014002668A patent/MY171180A/en unknown
- 2013-04-02 SG SG11201405759UA patent/SG11201405759UA/en unknown
- 2013-04-02 NZ NZ700650A patent/NZ700650A/en not_active IP Right Cessation
- 2013-04-02 UY UY0001034721A patent/UY34721A/es not_active Application Discontinuation
- 2013-04-02 CN CN201380015594.7A patent/CN104169302A/zh active Pending
- 2013-04-02 EP EP13716138.6A patent/EP2834272B1/en active Active
- 2013-04-02 KR KR20147030831A patent/KR20150003256A/ko not_active Withdrawn
- 2013-04-02 JP JP2015504677A patent/JP6320993B2/ja not_active Expired - Fee Related
- 2013-04-02 BR BR112014024622A patent/BR112014024622A2/pt not_active IP Right Cessation
- 2013-04-02 SG SG10201608136SA patent/SG10201608136SA/en unknown
- 2013-04-03 AR ARP130101081A patent/AR090585A1/es unknown
2014
- 2014-09-17 IL IL234707A patent/IL234707A0/en unknown
- 2014-09-29 PH PH12014502184A patent/PH12014502184A1/en unknown
- 2014-09-30 CL CL2014002631A patent/CL2014002631A1/es unknown
- 2014-10-30 CO CO14241139A patent/CO7121320A2/es unknown
2018
- 2018-01-03 IL IL256716A patent/IL256716A/en unknown

Also Published As

Publication number	Publication date
CA2868907C (en)	2022-01-04
TW201343675A (zh)	2013-11-01
EA201491827A1 (ru)	2015-03-31
BR112014024622A2 (pt)	2017-08-08
MX365690B (es)	2019-06-11
AU2013243644B2 (en)	2018-02-08
MY171180A (en)	2019-09-30
IL256716A (en)	2018-03-29
KR20150003256A (ko)	2015-01-08
NZ700650A (en)	2017-02-24
CO7121320A2 (es)	2014-11-20
SG11201405759UA (en)	2014-11-27
MX2014011898A (es)	2014-11-12
US20130259876A1 (en)	2013-10-03
EP2834272A2 (en)	2015-02-11
IL234707A0 (en)	2014-11-30
UY34721A (es)	2013-10-31
AU2013243644C1 (en)	2018-05-10
PH12014502184A1 (en)	2014-12-10
JP6320993B2 (ja)	2018-05-09
CA2868907A1 (en)	2013-10-10
WO2013152001A3 (en)	2013-12-27
TWI619729B (zh)	2018-04-01
AU2013243644A1 (en)	2014-10-23
HK1207092A1 (en)	2016-01-22
WO2013152001A2 (en)	2013-10-10
JP2015514110A (ja)	2015-05-18
AR090585A1 (es)	2014-11-26
CN104169302A (zh)	2014-11-26
US9790273B2 (en)	2017-10-17
SG10201608136SA (en)	2016-11-29
EP2834272B1 (en)	2020-06-24

Publication	Publication Date	Title
CL2014002631A1 (es)	2015-01-16	Anticuerpos anti - hla - b*27 y usos de estos
IL269045A (en)	2019-10-31	Aptamers and uses thereof
CL2016001212A1 (es)	2016-12-09	Moduladores de aplnr y usos de estos
CL2015001321A1 (es)	2015-07-17	Anticuerpos anti-ceacam5 y usos de éstos
BR112015003354A2 (pt)	2017-08-08	composições e métodos de microcápsula
CL2016000981A1 (es)	2017-01-13	Formulaciones de estrigolactona y sus usos
CL2015000640A1 (es)	2016-07-22	Variantes de hppd y métodos de uso
EP2930714A4 (en)	2016-11-09	Singing voice synthesizing system and singing voice synthesizing method
PT2817338T (pt)	2017-11-13	Moduladores de dll3 e métodos de utilização
DK3360964T3 (da)	2019-10-28	Crispr-baseret genommodifikation og -regulering
EP2859439A4 (en)	2016-03-30	CLOUD APPLICATION DEPLOYMENT
DK2919796T3 (da)	2021-05-31	Brug af akkermansia til behandling af stofskiftesygdomme
EP2879709A4 (en)	2016-03-23	MODULATION OF IMMUNE REACTION
EP2839005A4 (en)	2016-10-05	MIRNA MODULATORS OF THERMOGENESIS
CO7030961A2 (es)	2014-08-21	Benzotienilo-pirrolotriazinas disustituidas y sus usos
EP2864479A4 (en)	2016-06-08	MODULATION OF THE UBE3A ATS EXPRESSION
SI3715345T1 (sl)	2024-07-31	Priprava zaviralca lfa-1
EP4144845C0 (en)	2024-04-24	ANTISENSE COMPOUNDS AND THEIR USES
SI3513806T1 (sl)	2023-04-28	Sestava imunogena
HRP20180872T1 (hr)	2018-07-13	Životinjska hrana i postupak njezine pripreme
EP2983661C0 (en)	2024-05-29	OXABICYCLOHEPTANE AND OXABICYCLOHEPTENE FORMULATIONS
EP4066849C0 (en)	2025-03-05	DAPTOMYCIN FORMULATIONS AND THEIR USES
PT2956476T (pt)	2020-02-21	Moléculas de ligação e usos destas
EP2997047A4 (en)	2016-11-23	heparansulphates
IL237397B (en)	2018-10-31	Bacterial strain and a composition comprising the bacterial strain